logo
Drunk Elephant's Latest Product Offering Addresses ‘Concerns That We Heard From Our Customers': ‘Felt Like A Natural Next Step'

Drunk Elephant's Latest Product Offering Addresses ‘Concerns That We Heard From Our Customers': ‘Felt Like A Natural Next Step'

Forbes04-06-2025
Drunk Elephant's Plump-C Tripeptide Lippe Mask is available to shop June 10.
Drunk Elephant's latest product offering sees the company enter a category it hasn't expanded upon in a decade—lips.
The brand's new Plump-C Tripeptide Lippe Mask launches June 10, making it only the second lip product in the Drunk Elephant arsenal. The mask—which the company calls 'a restorative anytime treatment to moisturize, plump and protect lips'—follows the Drunk Elephant Lippe Balm in terms of products targeting lips.
The Lippe Mask is only the brand's second product offering targeting lips.
'If there's one thing I can't stand, it's dry, chapped lips, so the one thing that's always in my bag or my pocket is Lippe,' founder Tiffany Masterson wrote in a note accompanying the new product. 'As much as I love it, I wanted something that addressed deepening lip lines, uneven texture and chronic dryness on the lips. That's how Plump-C Tripeptide Lippe Mask was born.'
Masterston continued that 'Plump-C is the longest-lasting moisture I've ever tried,' adding that it's clinically proven to smooth lines, even out texture and leave lips 'feeling deeply moisturized and plumper.'
'It's real lip service,' she concluded.
Tiffany Masterson attends the Drunk Elephant House Of Drunk pop-up on June 10, 2019 in New York ... More City. (Photo byfor Drunk Elephant)
The Lippe Mask can be used morning, night or as often as needed, the company advised. Speaking to me exclusively, Drunk Elephant's vice president of research and product development Nathan Rivas says that the new product 'is a richer version of Lippe Balm that plumps and restores.'
Lippe Balm, he tells me, can be used for daily lip care, with the Lippe Mask stepping in 'as an anytime restorative treatment' when looking to firm and moisturize dry, flaky lips, 'making them softer, smoother and plumper-looking.'
'We're constantly questioning what's possible—as well as what's missing—and that's where some of the most interesting formula directions come from,' Rivas says.
The company said the product can be used morning, night or whenever needed.
The new product launch comes after a difficult 2024 for Drunk Elephant. In creating the Lippe Mask, the company 'answered concerns that we heard from our customers,' Rivas says, specifically in the areas of lip lines, loss of lip volume and 'a need for more intensive degree of moisture.' He calls the Lippe Mask 'an evolution in Lippe Balm.'
'We pushed to answer those concerns while also challenging the limits of what this type of formula could do for lips, including actives that aren't typical for lip masks,' he tells me. 'Vitamin C and peptides, for example, are both preventative—helping to defend skin against free radicals and preserve healthy collagen—and a treatment, as they help improve concerns like firmness and elasticity.'
The Lippe Mask follows the Lippe Balm in Drunk Elephant's lip product offerings and comes a decade ... More after the Lippe Balm first came to market.
'Lippe Mask felt like a natural next step, as our best formulas are those that happen based on filling a consumer need,' Rivas tells me. 'The OG Lippe Balm is a staple for sure, though when your lips really want for more—to restore dry, flaky lips with deeper moisture—it doesn't quite meet those needs. That's how Lippe Mask was born.'
The Lippe Mask retails for $28 will be available at Sephora and Ulta—as well as both retailers' websites—as well as drunkelephant.com beginning Tuesday.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Google should 'walk away' from Waymo
Why Google should 'walk away' from Waymo

Yahoo

time26 minutes ago

  • Yahoo

Why Google should 'walk away' from Waymo

Needham & Company senior media and internet analyst Laura Martin joins Market Domination with Josh Lipton to explain why Alphabet (GOOG, GOOGL) should ditch Waymo and focus on generative artificial intelligence (AI) instead. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Related videos The £70bn pension tax raid Reeves may not be able to resist 10 shares I wouldn't want to hold in a stock market crash After falling 16% in a day, this stock's on my list of shares to buy in August This FTSE 250 trust is easily beating the global index in 2025. Time to buy? Sign in to access your portfolio

EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million
EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million

Yahoo

time26 minutes ago

  • Yahoo

EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million

EMCOR Group recently announced a regular quarterly cash dividend of $0.25 per common share, to be paid on July 31, 2025. This steady dividend approach aligns with the company's robust quarterly performance, which saw net income rise to $241 million and EPS increase substantially year-over-year. Additionally, the ongoing share buyback program has strengthened shareholder returns. Despite the broader market's moderate growth of 1.4% over the past week and 17% over the past year, EMCOR's notable share repurchases and solid financial outcomes appear to have amplified investor confidence, contributing to the company's impressive 55% stock price surge last quarter. We've spotted 1 risk for EMCOR Group you should be aware of. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. EMCOR Group's recent announcement of a quarterly dividend and the implementation of its share buyback program underline its commitment to enhancing shareholder returns. Despite a potential downside to the current share price of US$635.06, which exceeds the consensus analyst price target of US$549.57 by 13.46%, these actions could continue to buoy investor confidence. The company's performance over the past five years, with a total return exceeding 844.60%, showcases its robust long-term trajectory. In the last year, EMCOR's share performance exceeded both the broader market's 17.2% and the US Construction industry's 54.2% return, highlighting its strong standing relative to peers. The successful integration of acquisitions and strategic diversification into sectors like data centers and healthcare is anticipated to impact future revenue positively. This, coupled with operational efficiencies and strong revenue collaboration, may reinforce earnings projections. However, EMCOR's earnings forecasts of a 6.2% annual growth rate lag behind the broader market's 14.9% forecast, which could present challenges in meeting broader industry expectations. The company's impressive share price rise of 55% last quarter signals optimism, though its current value being above the target may indicate overvaluation concerns. Nevertheless, the consistent cash flow and healthy margins underscore its potential resilience against margin pressures, supply chain challenges, and other economic uncertainties. As analysts estimate revenue growth to 7.9% annually over the next three years, any tangible improvement in operational metrics could shift the valuation outlook positively. Unlock comprehensive insights into our analysis of EMCOR Group stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include EME. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

Yahoo

time26 minutes ago

  • Yahoo

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store